Form 4: ResMed Executive Michael J. Rider Reports Share Transactions

ResMed's Global General Counsel, Michael J. Rider, reported a gift of 173 shares and the sale of 74 shares under a pre-arranged trading plan.

Summary

• Michael J. Rider, Global General Counsel of ResMed, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On November 29, 2024, Mr. Rider gifted 173 shares of ResMed common stock to Fidelity Charitable, a donor-advised fund.
• Mr. Rider does not retain any beneficial interest, control, or dispositive power over these gifted shares.
• On December 2, 2024, Mr. Rider sold 74 shares of ResMed common stock at a price of $248.91 per share.
• This sale was executed under a Rule 10b5-1 trading plan adopted on May 11, 2024.
• Following these transactions, Mr. Rider's direct holdings decreased from 9,187 to 9,113 shares.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. The use of a 10b5-1 plan indicates a planned transaction.

Industry Context

This is a routine filing related to insider trading activity and is common for executives of publicly traded companies. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a standard practice among executives at publicly traded companies like ResMed to manage their stock transactions.
• Similar filings are regularly seen from executives at comparable medical device companies such as Medtronic (MDT) and Stryker (SYK), reflecting routine stock transactions.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate any significant change in the company's outlook.

Key Dates

Keywords

ResMed, RMD, Form 4, insider trading, beneficial ownership, Rule 10b5-1, stock transaction, Michael J. Rider, executive, share sale, share gift